Davy Research

Amryt Pharma (AMYT.L, AMYT LN)

  • 44.0
  • 274.8
  • 61.1

Company Profile

Formed in 2015, Amryt Pharma acquires, develops and commercialises therapies for orphan (rare) diseases, diseases that have small rates of prevalence among country populations. Amryt is not involved in drug discovery but acquires its pipeline through the acquisition and in-licensing of orphan therapies. The company currently has four assets in its portfolio (AP101, AP102, AP103 and Lojuxta) that are targeting multiple orphan indications. These therapies span both development and commercial stages of the lifecycle. Amryt also reports modest revenues from Imlan, the company's derma-cosmetics range of products. Imlan is considered a non-core part of the company's portfolio.


Major Shareholders%
Software AG - Siftung22.3
Cathal Friel12.0
Axa 9.8
Raglan Road Capital Limited9.0
Joseph Wiley7.6
  • AMRYT PHARMA

    Closing Price (p): 16.0

  • RATING 14/09/17

  • PREVIOUS RATING

Analyst(S)

COMPANY DATA

UPCOMING EVENTS

  • There are no upcomming events at present